Share your videos with the world

Sign Up | Log In | Help  

   
 
Search // non-drug
Results 1-12 of 12 for ' non-drug ' (0 seconds)
The Ad Council, the largest producer of public service campaigns in the U.S., in partnership with Viacom, home to premier global brands in media and entertainment, and non-profit leader Facing Addiction today launched the PSA campaign “LISTEN” to ignite a national conversation about drug and alcohol addiction as a public health epidemic, and empower those impacted by substance use disorders. While past PSA campaigns have traditionally focused on the perspective of those at risk, urging them to eliminate all substance use, “LISTEN” addresses the support system of people who are also affected by this crisis. Using powerful stories that portray the modern faces of addiction and recovery, the campaign looks to remove the stigma attached to substance misuse through the act of informed, compassionate listening. The campaign’s website, heretolisten.com, and Facing Addiction's Resource Hub provides important tools and information to help people start a productive conversation with their friends and loved ones and to support the more than 45 million Americans directly impacted by addiction. To view the multimedia release go to: http://www.multivu.com/players/English/8029751-ad-council-listen-psa-addiction-drug-alcohol-substance-abuse/
Categories // Miscellaneous 
Added: 2185 days ago by MultiVuVideos
Runtime: 1m0s | Views: 401 | Comments: 0
Not yet rated
 

 

 

LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world. One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom. “Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.” To view the multimedia release go to: http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Categories // Miscellaneous 
Added: 2268 days ago by MultiVuVideos
Runtime: 5m11s | Views: 538 | Comments: 0
Not yet rated
 

 

 

Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
Added: 2858 days ago by MultiVuVideos
Runtime: 0m53s | Views: 616 | Comments: 2
Not yet rated
 

 

 

Just back from rehab, Mary Rose returns to her regular hang-out in pursuit of her “would-be” soul mate, Ryan. She is devastated when he shows up with another girl… and not just any girl either… a really pretty hippie girl, who is older, and maybe even cooler. The True Diary of Mary Rose. Find out more at http://dearnobodydiary.com non-fiction/ YA
Tags // teen  diary  love  addiction  drug  abuse  bullying  mary  rose  go  ask  alice  gillian  mccain  legs  mcneil  ya 
Categories // Miscellaneous 
Added: 3183 days ago by cosproductions
Runtime: 1m12s | Views: 723 | Comments: 0
Not yet rated
 

 

 

Mary Rose just wants to fit in and make friends…but that’s not that easy when you’re carrying around a deadly secret. Find out more at dearnobodydiary.com. YA, Non-Fiction
Tags // teen  diary  addiction  drug  abuse  bullying  mary  rose  go  ask  alice  gillian  mccain  legs  mcneil  friendship  ya  rope  swing  dear 
Categories // Miscellaneous 
Added: 3202 days ago by cosproductions
Runtime: 1m14s | Views: 1112 | Comments: 0
    
 

 

 

They say that high school is supposed to be the best time of your life. But what if that’s just not true? More than anything, Mary Rose wants to fit in. She’ll do whatever it takes to make that happen, even if it costs her her life. Her compelling story will inspire readers—and remind them that they are not alone. Find our more at https://www.facebook.com/DEARNOBODY Dear Nobody The True Diary of Mary Rose YA and non-fiction
Tags // teen  diary  go  ask  alice  addiction  drug  abuse  secrets  tweak  bullying  dear  nobody  friends  mary  rose  book  trailer 
Categories // Miscellaneous  Family 
Added: 3211 days ago by cosproductions
Runtime: 1m17s | Views: 657 | Comments: 1
   
 

 

 

InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids. To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Added: 3748 days ago by MultiVuVideos
Runtime: 5m9s | Views: 1545 | Comments: 0
Not yet rated
 

 

 

According to a recent national survey, 17.1 percent of Americans lack health insurance, and more than nine million of the nation’s uninsured rely on federally qualified health centers (FQHC), non-profit community clinics and free clinics each year for primary care. While these clinics serve the critical health care needs of the uninsured, patients oftentimes cannot afford the medications prescribed by the clinic’s physicians, or navigate a fragmented system that only offers partial solutions. This is a particularly growing problem for America’s working poor. Today, Medco Foundation and Dispensary of Hope (DOH), a not-for-profit pharmacy-focused social venture for the uninsured, introduced a new, national initiative to substantially improve the supply, delivery and management of critical prescription drugs to thousands of uninsured Americans who are managing a chronic illness. To view Multimedia News Release, go to http://www.multivu.com/mnr/54424-medco-dispensary-of-hope-prescription-drug-program-clinics-uninsured
Categories // News and Politics 
Added: 4006 days ago by MultiVuVideo
Runtime: 2m19s | Views: 5468 | Comments: 0
Not yet rated
 

 

 

Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition. The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting. To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Categories // Business  Science and Technology 
Added: 4021 days ago by MultiVuVideos
Runtime: 1m22s | Views: 4126 | Comments: 1
Not yet rated
 

 

 

Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from the Research in Severe Asthma (RISA) Trial, demonstrating the long-term safety of bronchial thermoplasty (BT) in patients treated with the Company’s AlairTM Bronchial Thermoplasty System. Follow-up data demonstrate that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with BT. Results were presented today at the annual European Respiratory Society (ERS) Congress in Amsterdam by Michel Laviolette, M.D., Professor of Medicine, Institut universitaire de cardiologie et de pneumologie at Université Laval in Québec City, Canada. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/bostonscientific/52128/
Categories // People and Blog 
Added: 4139 days ago by MultiVuVideos
Runtime: 5m40s | Views: 5894 | Comments: 0
Not yet rated
 

 

 

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Categories // News and Politics 
Added: 4261 days ago by MultiVuVideo
Runtime: 2m15s | Views: 7079 | Comments: 0
Not yet rated
 

 

 

As soon as you start feeling run down or have other flu-like symptoms, take Oscillococcinum. Oscillo® is supported by published clinical studies, as well as more than 65 years of use throughout the world. -Clinical studies show that Oscillo reduces the severity and duration of flu-like symptoms such as headache, body aches, chills and fever -Great taste and convenient to take -No side effects; no drug interactions; non-drowsy -Safe for everyone 2 years of age and older To view Multimedia News Release, go to http://www.multivu.com/players/English/45775-Boiron-Oscillococcinum/
Categories // News and Politics 
Added: 4382 days ago by MultiVuVideo
Runtime: 1m53s | Views: 6529 | Comments: 0
Not yet rated
 

 

 

Page 1 of 1  |  Go to page   



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2023 ClipMoon.com. All rights reserved.